Cargando…
Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus
BACKGROUND: The amyloid-β oligomers, consisting of 10–20 monomers (AβO(10–20)), have strong neurotoxicity and are associated with cognitive impairment in Alzheimer’s disease (AD). However, their role in patients with idiopathic normal pressure hydrocephalus (iNPH) is poorly understood. OBJECTIVE: We...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461658/ https://www.ncbi.nlm.nih.gov/pubmed/34275898 http://dx.doi.org/10.3233/JAD-210226 |
_version_ | 1784572034446000128 |
---|---|
author | Kawamura, Kaito Miyajima, Masakazu Nakajima, Madoka Kanai, Mitsuyasu Motoi, Yumiko Nojiri, Shuko Akiba, Chihiro Ogino, Ikuko Xu, Hanbing Kamohara, Chihiro Yamada, Shinya Karagiozov, Kostadin Ikeuchi, Takeshi Kondo, Akihide Arai, Hajime |
author_facet | Kawamura, Kaito Miyajima, Masakazu Nakajima, Madoka Kanai, Mitsuyasu Motoi, Yumiko Nojiri, Shuko Akiba, Chihiro Ogino, Ikuko Xu, Hanbing Kamohara, Chihiro Yamada, Shinya Karagiozov, Kostadin Ikeuchi, Takeshi Kondo, Akihide Arai, Hajime |
author_sort | Kawamura, Kaito |
collection | PubMed |
description | BACKGROUND: The amyloid-β oligomers, consisting of 10–20 monomers (AβO(10–20)), have strong neurotoxicity and are associated with cognitive impairment in Alzheimer’s disease (AD). However, their role in patients with idiopathic normal pressure hydrocephalus (iNPH) is poorly understood. OBJECTIVE: We hypothesized that cerebrospinal fluid (CSF) AβO(10–20) accumulates in patients with iNPH, and its clearance after CSF shunting contributes to neurological improvement. We measured CSF AβO(10–20) levels before and after CSF shunting in iNPH patients evaluating their diagnostic and prognostic role. METHODS: We evaluated two iNPH cohorts: “evaluation” (cohort-1) with 32 patients and “validation” (cohort-2) with 13 patients. Comparison cohorts included: 27 neurologically healthy controls (HCs), and 16 AD, 15 Parkinson’s disease (PD), and 14 progressive supranuclear palsy (PSP) patients. We assessed for all cohorts CSF AβO(10–20) levels and their comprehensive clinical data. iNPH cohort-1 pre-shunting data were compared with those of comparison cohorts, using cohort-2 for validation. Next, we compared cohort-1’s clinical and CSF data: 1) before and after CSF shunting, and 2) increased versus decreased AβO(10–20) levels at baseline, 1 and 3 years after shunting. RESULTS: Cohort-1 had higher CSF AβO(10–20) levels than the HCs, PD, and PSP cohorts. This result was validated with data from cohort-2. CSF AβO(10–20) levels differentiated cohort-1 from the PD and PSP groups, with an area under receiver operating characteristic curve of 0.94. AβO(10–20) levels in cohort-1 decreased after CSF shunting. Patients with AβO(10–20) decrease showed better cognitive outcome than those without. CONCLUSION: AβO(10–20) accumulates in patients with iNPH and is eliminated by CSF shunting. AβO(10–20) can be an applicable diagnostic and prognostic biomarker. |
format | Online Article Text |
id | pubmed-8461658 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-84616582021-10-08 Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus Kawamura, Kaito Miyajima, Masakazu Nakajima, Madoka Kanai, Mitsuyasu Motoi, Yumiko Nojiri, Shuko Akiba, Chihiro Ogino, Ikuko Xu, Hanbing Kamohara, Chihiro Yamada, Shinya Karagiozov, Kostadin Ikeuchi, Takeshi Kondo, Akihide Arai, Hajime J Alzheimers Dis Research Article BACKGROUND: The amyloid-β oligomers, consisting of 10–20 monomers (AβO(10–20)), have strong neurotoxicity and are associated with cognitive impairment in Alzheimer’s disease (AD). However, their role in patients with idiopathic normal pressure hydrocephalus (iNPH) is poorly understood. OBJECTIVE: We hypothesized that cerebrospinal fluid (CSF) AβO(10–20) accumulates in patients with iNPH, and its clearance after CSF shunting contributes to neurological improvement. We measured CSF AβO(10–20) levels before and after CSF shunting in iNPH patients evaluating their diagnostic and prognostic role. METHODS: We evaluated two iNPH cohorts: “evaluation” (cohort-1) with 32 patients and “validation” (cohort-2) with 13 patients. Comparison cohorts included: 27 neurologically healthy controls (HCs), and 16 AD, 15 Parkinson’s disease (PD), and 14 progressive supranuclear palsy (PSP) patients. We assessed for all cohorts CSF AβO(10–20) levels and their comprehensive clinical data. iNPH cohort-1 pre-shunting data were compared with those of comparison cohorts, using cohort-2 for validation. Next, we compared cohort-1’s clinical and CSF data: 1) before and after CSF shunting, and 2) increased versus decreased AβO(10–20) levels at baseline, 1 and 3 years after shunting. RESULTS: Cohort-1 had higher CSF AβO(10–20) levels than the HCs, PD, and PSP cohorts. This result was validated with data from cohort-2. CSF AβO(10–20) levels differentiated cohort-1 from the PD and PSP groups, with an area under receiver operating characteristic curve of 0.94. AβO(10–20) levels in cohort-1 decreased after CSF shunting. Patients with AβO(10–20) decrease showed better cognitive outcome than those without. CONCLUSION: AβO(10–20) accumulates in patients with iNPH and is eliminated by CSF shunting. AβO(10–20) can be an applicable diagnostic and prognostic biomarker. IOS Press 2021-08-31 /pmc/articles/PMC8461658/ /pubmed/34275898 http://dx.doi.org/10.3233/JAD-210226 Text en © 2021 – The authors. Published by IOS Press https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Kawamura, Kaito Miyajima, Masakazu Nakajima, Madoka Kanai, Mitsuyasu Motoi, Yumiko Nojiri, Shuko Akiba, Chihiro Ogino, Ikuko Xu, Hanbing Kamohara, Chihiro Yamada, Shinya Karagiozov, Kostadin Ikeuchi, Takeshi Kondo, Akihide Arai, Hajime Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus |
title | Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus |
title_full | Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus |
title_fullStr | Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus |
title_full_unstemmed | Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus |
title_short | Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus |
title_sort | cerebrospinal fluid amyloid-β oligomer levels in patients with idiopathic normal pressure hydrocephalus |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461658/ https://www.ncbi.nlm.nih.gov/pubmed/34275898 http://dx.doi.org/10.3233/JAD-210226 |
work_keys_str_mv | AT kawamurakaito cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus AT miyajimamasakazu cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus AT nakajimamadoka cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus AT kanaimitsuyasu cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus AT motoiyumiko cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus AT nojirishuko cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus AT akibachihiro cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus AT oginoikuko cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus AT xuhanbing cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus AT kamoharachihiro cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus AT yamadashinya cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus AT karagiozovkostadin cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus AT ikeuchitakeshi cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus AT kondoakihide cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus AT araihajime cerebrospinalfluidamyloidboligomerlevelsinpatientswithidiopathicnormalpressurehydrocephalus |